Skip to main content
Skip to section navigation
Skip to footer
Home
About
Overview
Management Team
Board of Directors
Advisory Board
Pipeline
Overview
XRx-008 for Autosomal Dominant Polycystic Kidney Disease
XRx-101 for Coronavirus/COVID-19
XRX-225 for Type 2 Diabetic Nephropathy
Publications
Technology
News
Press Releases
Events
Investors
Overview
News & Events
Presentations
Company Info
Financial Info
Stock Data
SEC Filings
SEDAR
Governance
Contact
Press Releases
News
News
Press Releases
Events
Year
All Years
2022
2021
2020
2019
2018
Sep 10, 2018 7:00am EDT
XORTX Announces Submission of Orphan Drug Designation Application
Aug 13, 2018 7:00am EDT
XORTX Submits FDA pre-IND Meeting Documents
Jun 28, 2018 8:59am EDT
XORTX Reports on Annual Special Meeting and Provides Corporate Update
Jun 08, 2018 7:00am EDT
XORTX Announces Filing of FDA pre-IND Meeting Request Letter
Jun 06, 2018 5:38pm EDT
XORTX to Commence Trading on the OTCQB Venture Market
May 08, 2018 7:00am EDT
XORTX Appoints Chairman
Apr 19, 2018 7:00am EDT
XORTX Announces PKD Foundation Collaboration
Mar 20, 2018 9:24pm EDT
XORTX Announces Issuance of Stock Options
Feb 27, 2018 7:30am EST
XORTX Therapeutics Provides Corporate Update
Feb 22, 2018 7:30am EST
XORTX Therapeutics Appoints Dave Matthews CFO
arrow_back
1…
2
3
4
5
6
7
8
9
10
11
arrow_forward
rss_feed
News RSS